Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Yes BOBO8989 - news that we get the permission for the initial afforestation project would be the kind of news that will lift the sp. On the subject of the current rate for Lumber futures, I don't buy that this is the problem affecting the sp. Sure, if Lumber futures go down, just like it swinging up again, will affect the sp - but, in my opinion, only marginally. The distressed selling of Rhino Ventures over a prolonged period was, in my opinion, what took the sp so low. After that, not unnaturally, other investors think there must be something wrong with the Company. The provisional figures for the year just past, prove quite clearly that they have done really well. Remember they did this despite the Covid pandemic, war in Europe where their market is historically strong. As a lth, I feel the trading outlook is excellent but patience is needed still with the sp.
Let's hope the afforestation project gets started soon.
Good points jamrock - given the size of your holding, have you emailed the Company to ask why we have had no update ?
Considering that Penny clearly alluded to wishing to update the market in the 4th quarter that has just passed.
I added Wednesday at 1.725 ahead of the announcement of 2022's trading figures. In a better market, I should be quids in for anticipating correctly that the figures would be good - but the sp is still down. You have to ask what does the market expect from Woodbois ? The prolonged distressed selling by Rhino Ventures must be the catalyst here - they're now down to 9% whereas they were nudging 29% I recall. Fortunately, Lombard Odier, which is now the largest declared holder at 14% is holding steady and has been a short-term funder of WBI.
Woodbois is still waiting for final approval of an afforestation project, which when approval is announced maybe the nudge we need to get the sp on the up again. Short of a political calamity in Gabon, I think the outlook is distinctly good for Woodbois and I'm confident we'll see really good growth this year in the shareprice.
Patience is the name of the game right now for us long-term holders. GLA
Irrespective of who is selling the LFT tests on Amazon, please can someone enlighten me what is MHC's link with FlowFlex ? Do we now any specific figures relating to MHC's business with FlowFlex to help us judge how MHC is doing ?
Bottom_feeder
Thanks for website find for Eroxon. I see the site says expected availability 15th January to 15th February. The Belgian website is managed by Shop-Apotheke BV, a small company with limited liability under Dutch law with a registered capital of €18,000 but small or large, this is the first time we've seen anything specific by way of sales info. As for pricing Euros 29.50 for 4 tubes - I recall seeing/hearing in the past comment from the FUM (Proactive discussion ?) that would sell for approx £5. I guess Eroxon would not be zero vat rated, so Euros 29.50 inc. vat and E/£ exchange rate is similar.
Gosh, after all these years of waiting, it is so good to see some tangible info - good luck all.
shal1000 - I guess you're looking for 3p if we're both talking about Woodbois. I'm looking for higher having subscribed at their 6p placing a while back although I've lowered my average a bit since. We'll have 2022 trading news soon if they follow to past form - would hope by next week at latest
PetitStVincent - I've liked all your consistently thoughtful analyses these past years. I am not surprised though that Coopers haven't yet promoted the product, having seemingly wasted 1 year of their 5 years contract. It's been clear to me that the BOD decided long ago to wait for FDA clearance. Remember, there is supposedly little in the way of active ingredients in DermaSys - or so I read somewhere in journals . I don't know what the latest on patent expiry is but the product at this base level of just DermaSys must be open to easier copycatting wouldn't you think ?
So, better to grab all the major markets at the outset to establish and maximise Eroxon's potential. I just hope Futura has got itself ready for the day the FDA decision lands.
Well done ace2326 - totally agree with you.
I tend to be more verbose & analytical in my posts on MHC, but at heart you are saying exactly what I am thinking.
Thanks ace2326
shal1000 - that's not been my experience over the years with WBI. I think it's a direct correlation of the really persistent selling by Rhino Ventures of their large holding - which at the various prices obtained looks like 'distressed selling' ? Perhaps related to the bitcoin meltdown as some posters suggested at the time.
There was a large SELL this morning:
09:09:28 1.62 3,237,830 clearly under the spread at the time 1.70-1.75p
But there was a later BUY:
12:15:05 1.746 1,350,000
I think this has been overdone and, as we are due provisional trading figures for 2022 soon, I'm confident we'll see a welcome return to growth in the share price. GLA
Does anyone else wonder if the amazing ramp we saw earlier last year was orchestrated by associates in some nebulous way to aid the massive selling down of Rhino Ventures holdings ?
Thanks smudge99 - I mistakenly quoted Genome Store in my post whereas you correctly stated it's Nell Health.
The company was acquired 6/2021 for £1,152,000 in shares plus £50,000 in cash and deferred consideration of £1m which we subsequently learned was not paid as they didn't meet performance criteria. I think the shares were originally allocated at 3.5p and we've seen a drip drip drop in the sp since then. So it's likely they would have been a seller of MHC shares since.
I have to wonder why the products came off Amazon in the first place, the MD having decided to give that market a try in the first place ?
Answering my own question, they were in a hurry to make up for the obvious delay in getting them manufactured. Something was badly wrong at the Genome Store - presumably the products didn't work under early tests - which is why MHC didn't honour the incentive bonus of £1 million in shares when they were originally acquired. But then we have to accept that the DNA test have not been selling. Apart from one spurious review mid-summer, we have seen no other reviews on TrustPilot nor on Amazon, the latter business encourages buyers to review good or bad. If my analysis is correct, so why put them back now ?
Again, answering my own question, my thoughts are that they are not selling from their extensive database of Covid customers either. I've received numerous marketing emails from the Company on each of the products. They're all attractive but but there's never been any marketing inducement - either outright promotional discount, or a softer one, say 'buy two, save x % - nor has they're been any publicity, product placing, newspaper reviews etc. that I've seen. I'm accepting that they haven't agreed a tie-up with say Boots because there is insufficient margin at the product price £45 + VAT to absorb the high take that Boots would want. If there is a positive in all this, it is my firm belief that Penny watches the pennies which is a good thing - but we do have cash in the Bank (or did) and now's the time to get these new products working - assuming that is the knowledge a customer would learn from taking up a test is truly worthwhile.
Penny clearly concluded her September statement:
"I want to thank each person who has delivered for MHC this year, doing so alongside the work being undertaken as we work towards a new portfolio and associated launches, which we are excited to share with the market in Q4."
In my view they have insufficient personnel to develop the products or manage the publicity of what they do have - look at TrustPilot, the reviews have all but dried up - in the last 10 which span back to early November, 3 were absolutely dreadful.
Penny mentioned something more exciting in that September statement:
"Development technology builds for new blood testing launch in Q4 2022"
I reckon this would be quite an advance allowing a whole host of new products and from my amateurish knowledge (based partly on seeing what Randox are doing) would offer MHC much better margins. If all this work is falling on just Penny and the Financial director's shoulders, then this would definitely explain the lack of promised updates.
We can't kid ourselves about the lack of market support for the shares when Company news has been lacking. Finally, could the current malaise at YourGene be impacting on us ? All in all, it's hard to know.
GLA
Crazyyear - as a very LTH, I'm definitely positive as to FUM's future but after reading your comments, I'm even more so.
I have to be honest and say, I hadn't seen all the detail you mention before. It looks like I've been a bit lax in my own ongoing research - thankfully it's all positive though.
Cheers Crazyyear.
It is not actually a binary choice as much depends upon other triggers such as Cooper announcing UK manufacture/sales - but going along with the question:
80p plus:
With FDA approval for over the counter sales - it will bounce to 80p within 2 or 3 days trading especially if it's announced early in the week. If that were the case, I could see it breaking £1 by the weekend but would expect it to pull back in the following week.
45p - 65p:
I don't see how the FDA can decline to allow OTC sales, given the cautious steps FUM has followed with the FDA over the past year. However, we know lobbying by interested parties is rife and there may be some form of words delaying OTC sales. That would hurt the SP in ways we cannot be sure but if it were matched by FUM announcing actual production in Europe/UK, then I don't foresee a calamity with the SP at all - we could in fact see a rise in this case too.
I’m disappointed there has been no update - and I take that as a negative that the new products are not performing. I haven’t seen any publicity and/or press placings and if that’s right and not just me saying it, then in my opinion that would account for low take-up.
However, at the current sp one can only wait and hope the Board recognise the need for publicity.
Interesting thoughts - soonbetime.
The sp prior to the covid awareness in early spring 2020 had been bumping along at around lows of 8p and had been languishing for a long time as I recall. We seem to be heading that way and the major difference this time is that the company’s pay bill is whoppingly higher.
Something has to change this time and a Polygon move seems a more likely scenario.
Whatever happens - all best wishes to everyone.
BruceJamieson - I did read your earlier comment and have noted your many comments which are usually one-liners which are easily prone to be misinterpreted. Viagra has been out of patent for 2 years and being such old news, I thought your point was that production by others could flood the market with viagra lookalikes - sorry for misinterpreting you.
But I'll raise you on your pithy comment "I think we can expect a 3 bagger" and make it a 4 bagger sometime in 2023.
Good luck all.
81lucky - if you’re implying that even if the FDA prove troublesome with their final approval the Board could still mage to succeed with the rest of the world contracts, I agree with you.
As we have respected Cooper already on board ready for the large European market, then I can see FUM can still go on to good things in the next quarter.
I’ve come to realise, that it is now a win/win share - it’s just a matter of how much the sp will benefit - will it be good or will it be even better ?